Potent Compounds Dosage Facility

Burns & McDonnell provided programming and current Good Manufacturing Practice (cGMP) design for a 65,000-square-foot Covidien research and small-scale pharmaceutical manufacturing facility.

Covidien uses the development suites for both potent and standard drug formulations as well as small-scale cGMP manufacturing operations, which primarily employ batch processing and concentrate on solid dosage formulations. The facility also houses a Drug Enforcement Administration (DEA) controlled substance vault, which includes stability chambers and controlled substance storage. The project upgraded building security to DEA standards and provided a data acquisition network for analytical chromatographs.